# Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

> **NCT00254202** · PHASE3 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 593 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Iloperidone
- **DRUG:** Ziprasidone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00254202
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-18
- **Primary completion:** 2006-09-26
- **Final completion:** 2007-03-21
- **Target enrollment:** 593 (ACTUAL)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00254202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00254202, "Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00254202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*